Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Dry Eye > Combined light therapy shows promise for treating Demodex-associated blepharitis
  • Dry Eye

Combined light therapy shows promise for treating Demodex-associated blepharitis

Ophthalmology 360

Combined intense pulsed light (IPL) and low-level light therapy is a safe and effective treatment for patients with Demodex-associated blepharitis that does not respond to standard therapies, leading to significant improvement in both clinical signs and patient symptoms without reported adverse effects, according to a study.

Researchers reviewed records from 17 patients (34 eyes) whose Demodex-associated blepharitis did not respond to standard therapies. Participants underwent an average of 8 treatment sessions involving IPL, along with 12 minutes of blue light followed by 12 minutes of red light.

The dual light approach led to significant improvements across multiple measures. Signs such as collarettes, lid margin saponification, conjunctival redness, and corneal staining all decreased after treatment, while dry eye symptoms improved on the DEQ-5 questionnaire. No treatment-related adverse events were reported.

Reference
Farrant S, Giannaccare G, Lim CHL, et al. Intense Pulsed Light Combined with Low Level Blue and Red Light Therapy for Demodex-Associated Blepharitis. Clin Ophthalmol. 2025;19:2575-2585. doi: 10.2147/OPTH.S521989. PMID: 40792188; PMCID: PMC12338316.

Share

Related Content

  • Dry Eye

Probiotic use tied to lower risk of primary open-angle glaucoma in adults with dry eye

  • Dry Eye

Statin use linked to a small increase in dry eye disease risk

  • Dry Eye

Analysis of FDA reports reveals widespread ocular adverse events linked to antidepressants

  • Cataract

Optimizing cataract surgery outcomes through dry eye management

  • Dry Eye

Preservative-free lubricants linked to improved dry eye symptoms in real-world study

  • Dry Eye

Spotlight on LACRIFILL®

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon